BioNTech names ex-Sobi chief Guido Oelkers as CEO, succeeding Ugur Sahin
Reuters2026/08/03 09:00- BioNTech named Guido Oelkers as chief executive, set to take office by Feb. 1, 2027, succeeding co-founder Ugur Sahin.
- Oelkers joins from Swedish Orphan Biovitrum, where he has been CEO since 2017; he has 30+ years in biotech and pharma leadership.
- Chief Medical Officer Ozlem Tureci will move to the management of a new standalone company to be led with Sahin; a successor search is underway.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
IX Biopharma seeks SGX-ST trading halt lift for shares in Singapore
No Public Money Behind El Salvador’s New Bitcoin, IMF Confirms
Crypto prices
More
